The effect of modified electroconvulsive therapy and lithium on oxidative stress status in bipolar disorder patients with depression episode
10.3969/j.issn.1002-0152.2016.12.006
- VernacularTitle:无抽搐电休克治疗与碳酸锂对双相障碍抑郁发作患者氧化应激水平的影响
- Author:
Qinyu LV
;
Chenxi BAO
;
Yanhua LU
;
Wei LU
;
Haiqi HU
;
Zhenghui YI
;
Yongguang HE
- Keywords:
Bipolar disorder;
Oxidative stress;
Modified electroconvulsive therapy;
Lithium
- From:
Chinese Journal of Nervous and Mental Diseases
2016;42(12):731-736
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine the effect of modified electroconvulsive therapy (MECT) on the plasma oxida-tive stress level in bipolar depression. Methods Forty-two patients with bipolar depression were randomly divided into two groups. The intervention group (n=18) received antidepressants and 12 times MECT for 6 weeks and the control group (n=24) received antidepressants and Li2CO3 for 6 weeks. The Chinese versions of the 17 items Hamilton Depression Rating Scale (HAMD-17), Young Mania Rating Scale (YMRS), Clinical Global Impression Scale (CGI-S) and Treatment Emergent Symptom Scale (TESS) were used to assess participants at baseline and after 6 weeks of treatment. The plasma levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and malondialdehyde (MDA)were detected at baseline and after 6 weeks to assess the level of oxidative stress. Results Repeated measures analysis of variance showed that the plasma level of SOD was higher in MECT group than in Li2CO3 group (F=15.26, P<0.01), and the level of MDA was higher in Li2CO3 group (F=18.18, P<0.01). The interactive effect of group and time was significant in GSH-Px level (F=6.39, P=0.02). The level of GSH-Px was lower in MECT group than in Li2CO3 group after 6 weeks (P<0.05). The CAT level was higher in the response patients than in non-response patients after 6 weeks (P<0.05). Con-clusions Both MECT treatment and Li2CO3 treatment can alter oxidative stress levels in patients with bipolar depression. The mechanisms underlying its therapeutic regimen may correct the imbalance of the plasma CAT level.
